Cardiothoracic & vascular anesthesia
Ecarin-based coagulation monitoring of argatroban in patients with heparin-induced thrombocytopenia: a prospective observational study
Authors' conclusion
This study presents ECA-CT as a reliable point-of-care test for monitoring argatroban concentration in patients with HIT. aPTT demonstrated a pronounced inability to track argatroban concentrations, especially when aPTT was >55 s.
Study context
- Population
- Patients with heparin-induced thrombocytopenia (HIT) undergoing cardiac surgery and receiving argatroban anticoagulation
- Participants
- 22 patients
- Exposure
- Ecarin clotting time (ECA-CT) vs activated partial thromboplastin time (aPTT)
- Outcome
- Correlation of ECA-CT and aPTT with plasma argatroban concentrations (functional assay)
- Follow-up
- Over 5 days
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Correlation with plasma argatroban concentration
| Group | Value | P |
|---|---|---|
| ECA-CT | r 0.881 (95% CI 0.790–0.934) | P<0.0001 |
| aPTT | r 0.12 (95% CI −0.182–0.412) | P=0.843 |
Value
ECA-CTr 0.881 (95% CI 0.790–0.934)
aPTTr 0.12 (95% CI −0.182–0.412)
P
ECA-CTP<0.0001
aPTTP=0.843
Observational data: associations, not effects.
Further findings
Argatroban concentration vs aPTT relationship
- Near-random association above aPTT >55 s; best described by a nonlinear approximation
Independent drivers of test variability
- Factor XII main independent driver of aPTT variability apart from argatroban
- ECA-CT independently affected by Factor II, X and XI apart from argatroban
Original publication
Ecarin-based coagulation monitoring of argatroban in patients with heparin-induced thrombocytopenia: a prospective observational study. Br J Anaesth. Published 5 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →